Tracleer for Digital Ulcers
Tracleer for Pulmonary Fibrosis
Tracleer for Pulmonary Hypertension
|Tracleer for Raynaud's
Tracleer for Scleroderma Renal Crisis
Tracleer for Skin Fibrosis
Tracleer® (bosentan) is made by Actelion Pharmaceuticals, Inc. The medication was initially developed for treatment of pulmonary hypertension, but has since proven useful in treating a variety of systemic scleroderma symptoms.
Tracleer (Bosentan) is proving useful for a variety of scleroderma symptoms, including pulmonary fibrosis, pulmonary hypertension, Raynaud's, and skin fibrosis. Bosentan is in a class of drugs called endothelin receptor antagonists by preventing an overproduction of endothelin.
Therefore, scleroderma researchers suggest that an early use of this drug should be considered for systemic scleroderma patients.
Tracleer (Bosentan) Drug Information including precautions, side effects and interactions. It may cause serious liver problems. Liver function should be monitored closely to decrease the risk of liver-related side effects. MedicineNet.
Effect of bosentan in pulmonary hypertension development in systemic sclerosis (SSc) patients with digital ulcers. We concluded that SSc patients with digital ulcers treated with bosentan seems to have less risk to develop pulmonary hypertension and to stabilize carbon monoxide diffusing capacity. PubMed, PLoS One, 2020 Dec 10;15(12):e0243651.
A patient-centered approach to the burden of symptoms in patients with scleroderma treated with Bosentan: A prospective single-center observational study. Bosentan therapy may indirectly influence functionality and quality of life in patients with scleroderma by reducing the burden of Raynaud's and digital ulcer-related symptoms. PubMed, Exp Ther Med, 2020 Mar;19(3):1739-1746.
Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study. Short-term treatment with bosentan simultaneously improves myocardial perfusion and function, as evaluated by highly sensitive and quantitative methods, in patients with SSc. Whether additional remodeling effect may be observed after longterm treatment with bosentan remains to be determined. J Rheumatol.
Pulmonary (lung) fibrosis, is a scarring of the lungs, and is the consequence of untreated pulmonary inflammation (alveolitis). It is often also referred to as interstitial lung disease. ISN.
Actelion Pathways. We provide help getting started on your new treatment, programs to help you pay for your medicine, and information about specialty pharmacies and mail delivery. Actelion.
Endothelial to Mesenchymal Transition (EndMT): Role in Physiology and in the Pathogenesis of Human Diseases. The identification of molecules and regulatory pathways involved in EndMT and the discovery of specific EndMT inhibitors should provide novel therapeutic approaches for various human disorders mediated by EndMT. PubMed, Physiol Rev, 2019 Apr 1;99(2):1281-1324. (Also see Macitentan (Opsumit™) and Fibroblasts)
Beneficial effects of long–term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis. Long–term treatment with bosentan reduces the risk of developing PAH in patients with systemic sclerosis. PubMed, J Int Med Res.
A patient-centered approach to the burden of symptoms in patients with scleroderma treated with Bosentan: A prospective single-center observational study. Bosentan therapy may indirectly influence functionality and quality of life in patients with scleroderma by reducing the burden of Raynaud's and DU-related symptoms. PubMed, Exp Ther Med, 2020 Mar;19(3):1739-1746. (Also see Raynaud's Treatments)
Effect of Bosentan in Scleroderma Renal Crisis (ScS-REINBO). This French clinical trial will be completed in June 2014. ClinicalTrials.gov.
Skin fibrosis is a process that follows chronic inflammation. Fibrotic tissue is like a scar tissue, thick, and rigid, due to an excess accumulation of protein below the skin. The diagnosis is clinical, and requires no laboratory or special testing. (Photo: Sclerodactyly, the culminating result of fibrosis affecting the hands of a systemic scleroderma patient.)
Systemic Scleroderma Symptoms (Main list; treatments are listed on each symptom page.)
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to: